|Mr. John R. Chiminski||Chairman & CEO||2.59M||6.95M||1964|
|Mr. Alessandro Maselli||Pres & COO||1.43M||N/A||1972|
|Mr. Wetteny N. Joseph||Sr. VP & CFO||936.22k||335.73k||1972|
|Mr. Steven L. Fasman||Sr. VP, Gen. Counsel & Corp. Sec.||1.04M||N/A||1963|
|Mr. Peter L. Buzy||Pres of Gene Therapy||535.1k||N/A||1960|
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment engages in the drug substance development and manufacturing; drug product clinical and commercial manufacturing; and integrated clinical and commercial supply solutions for protein and gene therapy biologics and specialty small molecules through injection, inhalation, and ophthalmic routes. The Oral Drug Delivery segment formulates, develops, and manufactures technologies and related integrated solutions for a range of oral dose forms, including its proprietary fast-dissolve Zydis tablets and conventional tablets, capsules, and sachet products. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has an agreement with Cycle Pharmaceuticals Ltd. to develop formulations targeting rare disease patients. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Catalent, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 5. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 3; Compensation: 3.